Alnylam Pharmaceuticals, Inc. (ALNY) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $284.11 -1.82%
Revenue Growth %: +70.6%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +70.6%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q1 EPS of ($0.25), $0.11 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.57 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- Restoration Hardware (RH) PT Raised to $130 at Stifel After Q1 Earnings
- Independent Bank receives regulatory approval for HCB Financial acquisition
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
